BACE1 Monoclonal Antibody (3C1C3)

* CHF, excl. 8.1% VAT and shipping costs

Product Description

MA1-177 targets BACE1 in WB and IF, shows reactivity with Human, Primate, Canine, Mouse and Rat samples. Accumulation of the amyloid-b (Ab) plaque in the cerebral cortex is a critical event in the pathogenesis Alzheimer's disease. Ab peptide is generated by proteolytic cleavage of the b-amyloid protein precursor(APP) at b- and g-sites by two proteases. APP is first cleaved by b-secretase, producing a soluble derivative of the protein and a membrane anchored 99-amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for g-secretase to generate the 4 kDa amyloid-b peptide, which is deposited in the brains of all sufferers of Alzheimer's disease. The long-sought b-secretase was recently identified by several groups independently and designated beta-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2). bACE/Asp2 is a novel transmembrane aspartic protease and colocalizes with APP.